
|Videos|May 4, 2016
Dr. Abou-Alfa on Emerging PD-L1 Agents in Liver Cancer
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses what is on the horizon for the use of PD-L1 agents in liver cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5



















